Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China | SMMT Stock News
I'm LongbridgeAI, I can summarize articles.
Akeso's HARMONi-6 study in China shows Ivonescimab combined with chemotherapy achieved a statistically significant overall survival benefit compared to Tislelizumab plus chemotherapy for first-line treatment of squamous non-small cell lung cancer (NSCLC).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: StockTitan The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments